Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01074138 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of KX2-391 for Treatment of Bone-Metastatic, Castration-Resistant Prostate Cancer
A Phase 2 study, sponsored by Athenex.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT01074138 is a Phase 2 study that has completed, run by Athenex. The registered enrollment target is 31 participants.
The verdict
NCT01074138, a Phase 2 study, has completed, sponsored by Athenex.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
The standard of care for patients with bone-metastatic, castrate-resistant prostate cancer is chemotherapy. If a patient elects not to choose chemotherapy, 70% will progress within 6 months. KX2-391 given orally twice a day for 6 months will be evaluated for its ability to delay/prevent disease progression in patients who have not had prior chemotherapy.
Interventions
- DRUG KX2-391
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2010-02 |
| Est. Completion | 2012-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01074138
The ClinicalTrials.gov registry entry for NCT01074138 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Athenex, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which KX2-391 is the first listed.
NCT01074138 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01074138 about?
NCT01074138 is a clinical study titled "Safety and Efficacy Study of KX2-391 for Treatment of Bone-Metastatic, Castration-Resistant Prostate Cancer". The standard of care for patients with bone-metastatic, castrate-resistant prostate cancer is chemotherapy. If a patient elects not to choose chemotherapy, 70% will progress within 6 months. KX2-391 given orally twice a day for 6 months will be evaluated for its ability to delay/prevent disease prog...
What is the current status of trial NCT01074138?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2010-02. Estimated completion is 2012-10.
What interventions are being tested in trial NCT01074138?
The interventions under investigation include: KX2-391 (DRUG).
Who is sponsoring clinical trial NCT01074138?
This trial is sponsored by Athenex, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.